Yifeng Pharmacy released its 2026 semi-annual report, with first-half attributable net profit of approximately 964 million yuan, up 9.51% year on year. The company's first-half operating revenue was approximately 12.13 billion yuan, up 3.48% year on year. Yifeng Pharmacy is mainly engaged in the omni-channel retail business of Chinese and Western patent medicines, traditional Chinese medicine decoction pieces, medical devices, health foods and other products. The company said revenue growth was mainly driven by organic growth at existing stores and expansion of franchise distribution business, while net profit growth benefited from revenue growth and a decline in expense ratio brought by cost reduction and efficiency improvement.
Yifeng PharmacyFirst-half net profit up 9.51% and revenue up 3.48%, with cost reduction improving margins.
